In this issue:
5-year efficacy and safety of secukinumab in AS patients
Referring early RA patients within 6 weeks vs 12 weeks after symptom onset
Using cumulative load to explain how BMI and daily walking relate to worsening knee cartilage damage over two years
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease
Therapeutic drug monitoring of adalimumab in RA
Real-world evidence of TNF inhibition in AS
High prevalence of spA-like MRI lesions in post-partum women
Effect of filgotinib on HRQoL in active psoriatic arthritis
DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs
Tocilizumab monotherapy for LVV
Please login below to download this issue (PDF)